Latest Safety News

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Aurelia Metals reports a robust September 2025 quarter, with production and costs aligning to plan and key projects advancing ahead of schedule. Significant growth in copper resources and reserves underpins a confident outlook for FY26 and beyond.

Saferoads Holdings Limited reported a solid quarterly profit of $346,000, driven by strong product sales including a key order from On-site Rentals. However, the company signals caution on sustaining profitability due to market uncertainties and inventory adjustments.

Native Mineral Resources and Great Divide Mining have agreed to jointly develop and process ore from the Yellow Jack Gold Project at NMR’s Blackjack Plant, aiming to enhance regional gold production.

Etherstack has secured a £14.2 million contract with the UK Home Office to provide critical software for the Emergency Services Network, reinforcing its global leadership in public safety communications.

Qoria Limited reported a strong start to FY2026, with annual recurring revenue climbing 25% year-on-year and record cash receipts of $46.3 million, prompting an upgrade to its full-year revenue guidance.

Krakatoa Resources is advancing its Zopkhito Antimony-Gold Project in Georgia with innovative drone LiDAR surveys and dual diamond drilling, moving closer to a maiden JORC resource amid rising demand for critical minerals.

Advanced Braking Technology Ltd has kicked off FY26 with a 21% rise in product sales revenue and a 66% jump in net profit before tax, underpinned by expanding international demand and progress in autonomous braking systems.

Cleanaway Waste Management faced a challenging FY25 with multiple fatalities prompting a safety overhaul, yet reported robust financial growth and reaffirmed FY26 guidance. Strategic acquisitions and operational improvements signal a determined path forward.

Yancoal’s September quarter report reveals stable coal output and a slight dip in realised prices, alongside a leadership change and strategic stake increase in the Moolarben Joint Venture.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.